Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan P Piccini

Showing results (441-450 of 538) with videos related to

Pageof 54
Sort By:
Journal of the American College of Cardiology|February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II TrialsJohn W Eikelboom, Hardi Mundl, John H Alexander, et al.
Heart Rhythm|November 10, 2021
Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval RegistryMikhael F El-Chami, Christophe Garweg, Saverio Iacopino, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Heart (British Cardiac Society)|June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationMichael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Pageof 54

Showing results (441-450 of 538) with videos related to

Sort By:
Pageof 54
Journal of the American College of Cardiology|February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II TrialsJohn W Eikelboom, Hardi Mundl, John H Alexander, et al.
Heart Rhythm|November 10, 2021
Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval RegistryMikhael F El-Chami, Christophe Garweg, Saverio Iacopino, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Heart (British Cardiac Society)|June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationMichael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Pageof 54